Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Atenolol + chlorthalidone** is an oral combination medication used primarily to treat high blood pressure (hypertension)[1][2][3][4][5][6][7]. It consists of two active components: - **Atenolol:** a cardioselective beta-1 adrenergic receptor blocker that decreases heart rate and cardiac workload by blocking catecholamine action on beta-1 receptors in the heart[1][2][4][5]. - **Chlorthalidone:** a thiazide-like diuretic that acts on the kidneys to increase sodium and water excretion, lowering blood pressure by reducing plasma volume[1][2][4][5]. The combination's antihypertensive effects are additive, with no mutual interference in bioavailability[2]. It is usually reserved for patients already stabilized on the individual agents and not recommended as initial therapy[1]. Atenolol + chlorthalidone is available as tablets in various strengths, such as 50 mg/25 mg and 100 mg/25 mg[2][5]. Common side effects include gastrointestinal upset, dizziness, gout, and electrolyte disturbances. Serious adverse reactions may include liver dysfunction, pancreatitis, severe bradycardia, and psychosis[1][2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on atenolol + chlorthalidone.